The Health 202: The era of bipartisan work on lowering drug prices might be over Paige Winfield Cunningham
with Alexandra Ellerbeck Dare we say it: The window for bipartisan work on drug pricing reform may be closed. Sen. Ron Wyden, top Democrat on the powerful Senate Finance Committee, is focusing on a wish-list item for Democrats but poison pill for the GOP: eliminating a ban on the federal government using its negotiating power to directly force lower drug prices under Medicare. “I think we’ve got to take bold action on prescription drug prices,” Wyden (Ore.) told reporters yesterday. “We’re going to be looking at all the tools to get this done.”
By MORGAN WINSOR, ERIN SCHUMAKER and EMILY SHAPIRO, ABC News (NEW YORK) — A pandemic of the novel coronavirus has now infected more than 91.7 million people worldwide and killed over 1.96 million of them, according to real-time data compiled by the Center for Systems Science and Engineering at Johns Hopkins University. Here’s how the [.]